Drugs / BCT-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03455140 | Aug 2018 → Jul 2022 | childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia | University of Birmingham | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCT-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03455140 ↗ |
| Modality | Protein / enzyme biologic | “a recombinant human arginase, BCT-100” PMID 38357205 ↗ Jan 2024 |
| Route | Intravenous | “BCT-100 was given intravenously over one hour at weekly intervals” PMID 38357205 ↗ Jan 2024 |